Patent · US Active

Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient

US10485808B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Marcus Schultze-Mosgau · Königstein, DE
Xinying Chang · Berlin, DE
Christian Seitz · Herrenberg, DE
Carsten Möller · Berlin, DE

Key dates

Filing date	Apr 2, 2018
Grant date	Nov 26, 2019
Priority date	—
Expiry date	Apr 2, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07J31/003
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.